Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET
Company Participants
Jennifer Good – President and Chief Executive Officer
Lisa Delfini – Chief Financial Officer
James Cassella – Chief Development Officer
Conference Call Participants
Faisal Khurshid – Leerink
Leland Gershell – Oppenheimer
Deb Chatterjee – JonesTrading
William Wood – B. Riley
Brandon Folkes – Rodman & Renshaw
Ryan Deschner – Raymond James
Operator
Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.
Various remarks that management makes during this conference call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those discussed in the Risk Factors section of the company's most recent quarterly report on Form 10-Q, which the company filed with the SEC this afternoon.
In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so even if its views change.
I would now like to turn the conference call over to Jennifer Good, Trevi’s President and CEO. Please go ahead.
Jennifer Good
Good afternoon, and thank you for joining us for our third quarter 2024 earnings call and business update. Joining me today on this call are my colleagues, Lisa Delfini, Trevi’s Chief Financial Officer; and Dr. James Cassella, Trevi’s Chief Development Officer. I will give an update on our trials and upcoming data milestones and Lisa will give a brief financial update. Then the three of us are happy to answer any questions.
First, I would like to take a minute and introduce you to Jim Cassella, who has recently joined our leadership team as our Chief Development Officer. As some of you may know, Jim has been on our Board of Directors for the past four years and has been a valuable advisor to me in that role. Jim has a deep background in neuroscience drug development with over 35 years working specifically on CNS therapies.